Europe Human Insulin Market 2020-2026 by Product Type (Drugs, Delivery Devices), Application (Type 1 Diabetes, Type 2 Diabetes, Others), Distribution Channel, and Country: Trend Forecast and Growth Opportunity

January 2020 | 111 pages | ID: ED1FDBA788B3EN
GMD Research

Abstracts

Europe human insulin market accounted for $7.61 billion in 2019 and will grow by 7.06% annually over forecast years.

Highlighted with 37 tables and 56 figures, this 111-page report “Europe Human Insulin Market 2020-2026 by Product Type (Drugs, Delivery Devices), Application (Type 1 Diabetes, Type 2 Diabetes, Others), Distribution Channel, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe human insulin market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. In this report 2019 is the base year for market analysis, with estimates and forecast covering 2020-2026. (Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view. The balanced (most likely) projection is used to quantify Europe human insulin market in every aspect of the classification from perspectives of Product Type, Application, Distribution Channel, and Country.

Based on product type, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

• Human Insulin Drugs
• Human Insulin Delivery Devices

Based on product, the Europe Human Insulin Drugs market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

• Modern Human Insulin (further segmented into Long-acting, Rapid- acting, Premixed by type; further segmented into Lantus, Apidra, Levemir, NovoRapid/ NovoLog, Novomix, Humalog, Others by brand)
• Traditional Human Insulin (further segmented into Short-acting, Intermediate & Rapid-acting, Premixed by type; further segmented into Humulin, Insuman, Novolin/Actrapid/Insulatard by brand)

Based on product, the Europe Human Insulin Delivery Devices market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

• Syringes
• Pens (further segmented into Disposable, Reusable, Pen needles)
• Pumps
• Others

Based on application, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes and Prediabetes

Based on distribution channel, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Geographically, the following national/local markets are fully investigated:

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe (further segmented into Russia, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)

For each of the aforementioned countries, market analysis and revenue data are available for 2019-2026. The breakdown of major national markets by Product Type, Application, and Distribution Channel over the study years (2019-2026) is included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in Europe human insulin market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players:

Astra Zeneca PLC
Biocon
Eli Lilly
Exir
Julphar
Novo Nordisk AS
Pfizer
Sanofi Aventis
Sedico
Wockhardt
(Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Contents

1 INTRODUCTION

1.1 Industry Definition and Research Scope
  1.1.1 Industry Definition
  1.1.2 Research Scope
1.2 Research Methodology
  1.2.1 Overview of Market Research Methodology
  1.2.2 Market Assumption
  1.2.3 Secondary Data
  1.2.4 Primary Data
  1.2.5 Data Filtration and Model Design
  1.2.6 Market Size/Share Estimation
  1.2.7 Research Limitations
1.3 Executive Summary

2 MARKET OVERVIEW AND DYNAMICS

2.1 Market Size and Forecast
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis

3 SEGMENTATION OF EUROPE MARKET BY PRODUCT TYPE

3.1 Market Overview by Product Type
3.2 Human Insulin Drugs
3.3 Human Insulin Delivery Devices

4 SEGMENTATION OF EUROPE HUMAN INSULIN DRUGS MARKET BY DRUG PRODUCT

4.1 Market Overview by Drug Product
4.2 Modern Human Insulin
  4.2.1 Modern Human Insulin by Type
  4.2.2 Modern Human Insulin by Brand
4.3 Traditional Human Insulin
  4.3.1 Traditional Human Insulin by Type
  4.3.2 Traditional Human Insulin by Brand

5 SEGMENTATION OF EUROPE HUMAN INSULIN DELIVERY DEVICES MARKET BY DEVICE PRODUCT

5.1 Market Overview by Product
5.2 Syringes
5.3 Pens
5.4 Pumps
5.5 Other Devices

6 SEGMENTATION OF EUROPE MARKET BY APPLICATION

6.1 Market Overview by Application
6.2 Type 1 Diabetes
6.3 Type 2 Diabetes
6.4 Gestational Diabetes and Prediabetes

7 SEGMENTATION OF EUROPE MARKET BY DISTRIBUTION CHANNEL

7.1 Market Overview by Distribution Channel
7.2 Hospital Pharmacies
7.3 Retail Pharmacies
7.4 Online Pharmacies

8 EUROPEAN MARKET 2019-2026 BY COUNTRY

8.1 Overview of European Market
8.2 Germany
8.3 UK
8.4 France
8.5 Spain
8.6 Italy
8.7 Rest of European Market

9 COMPETITIVE LANDSCAPE

9.1 Overview of Key Vendors
9.2 New Product Launch, Partnership, Investment, and M&A
9.3 Company Profiles
Astra Zeneca PLC
Biocon
Eli Lilly
Exir
Julphar
Novo Nordisk AS
Pfizer
Sanofi Aventis
Sedico
Wockhardt

10 INVESTING IN EUROPE MARKET: RISK ASSESSMENT AND MANAGEMENT

10.1 Risk Evaluation of Europe Market
10.2 Critical Success Factors (CSFs)
Related Reports and Products

List Of Tables

LIST OF TABLES

Table 1. Snapshot of Europe Human Insulin Market, 2019-2026
Table 2. Main Product Trends and Market Opportunities in Europe Human Insulin Market
Table 3. Europe Human Insulin Market by Product Type, 2019-2026, $ mn
Table 4. Europe Human Insulin Drugs Market by Product, 2019-2026, $ mn
Table 5. Europe Human Insulin Drugs Market: Modern Human Insulin by Type, 2019-2026, $ mn
Table 6. Europe Human Insulin Drugs Market: Modern Human Insulin by Brand, 2019-2026, $ mn
Table 7. Europe Human Insulin Drugs Market: Traditional Human Insulin by Type, 2019-2026, $ mn
Table 8. Europe Human Insulin Drugs Market: Traditional Human Insulin by Brand, 2019-2026, $ mn
Table 9. Europe Human Insulin Delivery Devices Market by Product, 2019-2026, $ mn
Table 10. Europe Human Insulin Delivery Devices Market: Pens by Product, 2019-2026, $ mn
Table 11. Europe Human Insulin Market by Application, 2019-2026, $ mn
Table 12. Europe Human Insulin Market by Distribution Channel, 2019-2026, $ mn
Table 13. Europe Human Insulin Market by Country, 2019-2026, $ mn
Table 14. Germany Human Insulin Market by Product Type, 2019-2026, $ mn
Table 15. Germany Human Insulin Market by Application, 2019-2026, $ mn
Table 16. Germany Human Insulin Market by Distribution Channel, 2019-2026, $ mn
Table 17. UK Human Insulin Market by Product Type, 2019-2026, $ mn
Table 18. UK Human Insulin Market by Application, 2019-2026, $ mn
Table 19. UK Human Insulin Market by Distribution Channel, 2019-2026, $ mn
Table 20. France Human Insulin Market by Product Type, 2019-2026, $ mn
Table 21. France Human Insulin Market by Application, 2019-2026, $ mn
Table 22. France Human Insulin Market by Distribution Channel, 2019-2026, $ mn
Table 23. Spain Human Insulin Market by Product Type, 2019-2026, $ mn
Table 24. Spain Human Insulin Market by Application, 2019-2026, $ mn
Table 25. Spain Human Insulin Market by Distribution Channel, 2019-2026, $ mn
Table 26. Italy Human Insulin Market by Product Type, 2019-2026, $ mn
Table 27. Italy Human Insulin Market by Application, 2019-2026, $ mn
Table 28. Italy Human Insulin Market by Distribution Channel, 2019-2026, $ mn
Table 29. Human Insulin Market in Rest of Europe by Country, 2019-2026, $ mn
Table 30. Europe Human Insulin Market by Key Vendor, 2019, $ mn
Table 31. Astra Zeneca PLC: Company Snapshot
Table 32. Astra Zeneca PLC: Business Segmentation
Table 33. Astra Zeneca PLC: Product Portfolio
Table 34. Astra Zeneca PLC: Revenue, 2016-2018, $ mn
Table 35. Astra Zeneca PLC: Recent Developments
Table 36. Risk Evaluation for Investing in Europe Market, 2019-2026
Table 37. Critical Success Factors and Key Takeaways

List Of Figures

LIST OF FIGURES

Figure 1. Research Method Flow Chart
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2026
Figure 4. Europe Human Insulin Market, 2019-2026, $ mn
Figure 5. Primary Drivers and Impact Factors of Europe Human Insulin Market
Figure 6. Primary Restraints and Impact Factors of Europe Human Insulin Market
Figure 7. Porter’s Fiver Forces Analysis of Europe Human Insulin Market
Figure 8. Breakdown of Europe Human Insulin Market by Product Type, 2019-2026, % of Revenue
Figure 9. Contribution to Europe 2020-2026 Cumulative Revenue by Product Type, Value ($ mn) and Share (%)
Figure 10. Europe Human Insulin Market: Human Insulin Drugs, 2019-2026, $ mn
Figure 11. Europe Human Insulin Market: Human Insulin Delivery Devices, 2019-2026, $ mn
Figure 12. Breakdown of Europe Human Insulin Drugs Market by Product, 2019-2026, % of Revenue
Figure 13. Contribution to Europe Human Insulin Drugs Cumulative Revenue by Product, 2020-2026, Value ($ mn) and Share (%)
Figure 14. Europe Human Insulin Market: Modern Human Insulin, 2019-2026, $ mn
Figure 15. Europe Modern Human Insulin Market: Long-acting, 2019-2026, $ mn
Figure 16. Europe Modern Human Insulin Market: Rapid- acting, 2019-2026, $ mn
Figure 17. Europe Modern Human Insulin Market: Premixed, 2019-2026, $ mn
Figure 18. Europe Modern Human Insulin Market: Lantus, 2019-2026, $ mn
Figure 19. Europe Modern Human Insulin Market: Apidra, 2019-2026, $ mn
Figure 20. Europe Modern Human Insulin Market: Levemir, 2019-2026, $ mn
Figure 21. Europe Modern Human Insulin Market: NovoRapid/ NovoLog, 2019-2026, $ mn
Figure 22. Europe Modern Human Insulin Market: Novomix, 2019-2026, $ mn
Figure 23. Europe Modern Human Insulin Market: Humalog, 2019-2026, $ mn
Figure 24. Europe Modern Human Insulin Market: Other Brands, 2019-2026, $ mn
Figure 25. Europe Human Insulin Market: Traditional Human Insulin, 2019-2026, $ mn
Figure 26. Europe Traditional Human Insulin Market: Short-acting, 2019-2026, $ mn
Figure 27. Europe Traditional Human Insulin Market: Intermediate & Rapid-acting, 2019-2026, $ mn
Figure 28. Europe Traditional Human Insulin Market: Premixed, 2019-2026, $ mn
Figure 29. Europe Traditional Human Insulin Market: Humulin, 2019-2026, $ mn
Figure 30. Europe Traditional Human Insulin Market: Insuman, 2019-2026, $ mn
Figure 31. Europe Traditional Human Insulin Market: Novolin/Actrapid/Insulatard, 2019-2026, $ mn
Figure 32. Breakdown of Europe Human Insulin Delivery Devices Market by Product, 2019-2026, % of Revenue
Figure 33. Contribution to Europe Human Insulin Delivery Devices Cumulative Revenue by Product, 2020-2026, Value ($ mn) and Share (%)
Figure 34. Europe Human Insulin Delivery Devices Market: Syringes, 2019-2026, $ mn
Figure 35. Europe Human Insulin Delivery Devices Market: Pens, 2019-2026, $ mn
Figure 36. Europe Human Insulin Delivery Devices Market: Pumps, 2019-2026, $ mn
Figure 37. Europe Human Insulin Delivery Devices Market: Other Devices, 2019-2026, $ mn
Figure 38. Breakdown of Europe Human Insulin Market by Application, 2019-2026, % of Revenue
Figure 39. Contribution to Europe 2020-2026 Cumulative Revenue by Application, Value ($ mn) and Share (%)
Figure 40. Europe Human Insulin Market: Type 1 Diabetes, 2019-2026, $ mn
Figure 41. Europe Human Insulin Market: Type 2 Diabetes, 2019-2026, $ mn
Figure 42. Europe Human Insulin Market: Gestational Diabetes and Prediabetes, 2019-2026, $ mn
Figure 43. Breakdown of Europe Human Insulin Market by Distribution Channel, 2019-2026, % of Revenue
Figure 44. Contribution to Europe 2020-2026 Cumulative Revenue by Distribution Channel, Value ($ mn) and Share (%)
Figure 45. Europe Human Insulin Market: Hospital Pharmacies, 2019-2026, $ mn
Figure 46. Europe Human Insulin Market: Retail Pharmacies, 2019-2026, $ mn
Figure 47. Europe Human Insulin Market: Online Pharmacies, 2019-2026, $ mn
Figure 48. Breakdown of European Human Insulin Market by Country, 2019 and 2026, % of Revenue
Figure 49. Contribution to Europe 2020-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 50. Human Insulin Market in Germany, 2019-2026, $ mn
Figure 51. Human Insulin Market in UK, 2019-2026, $ mn
Figure 52. Human Insulin Market in France, 2019-2026, $ mn
Figure 53. Human Insulin Market in Spain, 2019-2026, $ mn
Figure 54. Human Insulin Market in Italy, 2019-2026, $ mn
Figure 55. Human Insulin Market in Rest of Europe, 2019-2026, $ mn
Figure 56. Growth Stage of Europe Human Insulin Industry over the Forecast Period